Workflow
Financing
icon
Search documents
Mondelēz International Expands Sustainable Futures Portfolio Aiming to Accelerate Scalable Climate and Community Initiatives
Globenewswire· 2025-05-29 20:05
Core Viewpoint - Mondelēz International, Inc. is launching a new wave of impact-first investments through its Sustainable Futures Impact Investment platform, focusing on scalable solutions that address climate, community, and circularity, aligning with its sustainability strategy and Vision 2030 ambitions [1][4]. Investment Approach - The company employs a three-pronged investment strategy consisting of direct investments, fund investments, and technical assistance to scale promising solutions that generate measurable impact [2][4]. Direct Investments - New additions to the Sustainable Futures portfolio include investments in regenerative agriculture, inclusive financing, and circular packaging through innovative technology [4]. Fund Investments - Mondelēz International supports impact funds that align with its goal of catalyzing positive change across various geographies [3][4]. Technical Assistance - The company provides capacity-building support to early-stage ventures, helping validate their technologies through larger-scale pilots and scientific approaches [3][4]. Specific Investments - eAgronom is an ag-tech company aiding farmers in improving soil health and reducing carbon emissions, with over 1 million hectares under sustainable practices [5]. - ZIRO is a fintech startup providing affordable inventory financing to small merchants, aiming to reach approximately 100,000 merchants in three years [5]. - Pack2Earth is focused on replacing 60,000 metric tons of plastic packaging with compostable materials by 2028, part of a coalition supporting the Circulate Capital's Ocean Fund [5]. Impact Metrics - In 2024, investments in the Circulate Capital Ocean Fund contributed to circulating or avoiding over 7,600 tonnes of plastic, reducing more than 10,700 tonnes of GHG emissions, and creating over 34,900 tonnes in recycling infrastructure capacity across Southeast Asia and India [5]. Strategic Importance - Sustainability is a key pillar of Mondelēz International's growth strategy, with investments aimed at addressing challenges and creating long-term business resilience [6].
Endeavour Announces Completion of US$500 Million Senior Notes Offering and Results of Tender Offer
Globenewswire· 2025-05-29 16:41
NOT FOR DISTRIBUTION TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT, AND TO OBSERVE, ANY SUCH RESTRICTIONS. ENDEAVOUR ANNOUNCES COMPLETION OF US$500 MILLION SENIOR NOTES OFFERING AND RESULTS OF TENDER OFFER London, 29 May 2025 – Endeavour Mining plc ((LSE:EDV, TSX:EDV, OTCQX:EDVMF) (the “Company”) is pleased to announce that it has completed its previously ...
【前瞻分析】2025-2030年中国融资租赁行业企业数量及行业融资
Sou Hu Cai Jing· 2025-05-29 10:41
行业融资主要集中在企业服务、医疗、汽车等行业 行业主要上市公司:江苏金租(600901.SH)、国银金租(01606.HK)、渤海租赁(000415.SZ)、远东宏信 (03360.HK)、海通恒信(01905.HK)等 融资租赁行业已进入稳健发展阶段 中国融资租赁行业的单笔融资金额呈现波动性增长趋势。从2009年至2024年,行业单笔融资金额在部分 年份大幅波动,尤其是在2020年和2024年,单笔融资金额显著增大,显示出资本市场对融资租赁行业的 支持力度加大。整体来看,行业在不同年份的单笔融资金额受市场需求和经济环境影响,较低金额出现 在经济压力较大的年份,而在资本市场较为活跃的年份,融资金额则较为可观,表明市场对行业未来发 展的信心逐渐增强。 根据融资租赁行业的实际情况,企业的融资资金来源可分为内源融资和外源融资。内源融资是指企业通 过其内部资源进行资金筹集,例如,企业将经营利润、折旧等资金投入到相关项目中。外源融资则是指 企业通过借款、发行股票、债券或引入风险投资等方式,从外部渠道获得资金。 2018-2024年我国融资租赁行业的主要投融资事件如下: | 时间 | 融资企业 | 轮次 | 金额 | 投 ...
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
Globenewswire· 2025-05-28 20:05
Core Points - ORIC Pharmaceuticals, Inc. has announced a private placement of approximately 19.2 million shares at a price of $6.50 per share, representing an 18% premium to its 10-day trailing volume-weighted average price as of May 23, 2025 [1][2] - The financing is expected to generate gross proceeds of approximately $125 million, which will fund the company's operating plan into the second half of 2027 and support the primary endpoint readout from the first ORIC-944 Phase 3 trial in prostate cancer [1][3] Financing Details - The financing is led by SR One and includes participation from various institutional investors such as Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital [1][2] - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable [1] Use of Proceeds - ORIC intends to utilize the net proceeds from the financing for research and development of its clinical-stage product candidates, working capital, and general corporate purposes [3] - The combined proceeds from this financing and existing cash, cash equivalents, and marketable securities are expected to be sufficient to fund the current operating plan through the anticipated primary endpoint readout from the ORIC-944 Phase 3 trial [3] Company Overview - ORIC Pharmaceuticals is focused on developing treatments that address mechanisms of therapeutic resistance in cancer, with key product candidates including ORIC-944 for prostate cancer and ORIC-114 for multiple genetically defined cancers [6] - The company operates from offices in South San Francisco and San Diego, California [6]
Ad hoc announcement pursuant to Art. 53 of the SIX Swiss Exchange Listing Rules: gategroup announces pricing for new term loans and revolving credit facility financing
Globenewswire· 2025-05-28 18:41
gategroup Holding AG and its subsidiaries (together "gategroup") are announcing that they have priced a EUR 675 million term loan, a USD 500 million term loan and a multicurrency revolving credit facility in an amount of CHF 300 million (the “New Financing”). The key terms of the New Financing are as follows: CurrencyEUR USD MulticurrencyAmount675 million500 millionCHF 300 million Borrower(s) gategroup Finance International S.à.r.l (Luxembourg)gategroup Finance International S.à.r.l (Luxembourg) and gategro ...
Eagle Point Credit Co Inc.(ECC) - 2025 Q1 - Earnings Call Transcript
2025-05-28 15:02
Eagle Point Credit Company (ECC) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Company Participants Darren Daugherty - Managing DirectorThomas Majewski - Founder, Managing Partner, CEO & DirectorKenneth Onorio - CFO & COOMickey Schleien - MD - Equity ResearchRandy Binner - Managing DirectorErik Zwick - Managing Director, Equity ResearchSteven Bavaria - Editor/Publisher Operator Greetings, and welcome to Eagle Point Credit Company Incorporated First Quarter twenty twenty five Financial Results Conference Ca ...
安道麦B: 第十届董事会第十二次会议决议公告(英文版)
Zheng Quan Zhi Xing· 2025-05-27 11:07
Announcement of Resolution of the 12th The maximum price per Bond is ILS 1.466, and the term of bonds buyback shall be one year following the adoption of this resolution by the Board. The funding sources for the bonds buyback include internal sources and/or unutilized loans/credit facilities from banks/related parties. The Board further agrees to authorize the management of Solutions to make decision and enter into documents and arrangements in relation to such Buyback Plan performed through Solutions, as w ...
~US$140M Credit Facility Secured for the Minim Martap Bauxite Project
Globenewswire· 2025-05-26 02:32
Core Viewpoint - Canyon Resources Limited has secured a medium-term syndicated credit facility of approximately US$140 million from AFG Bank Cameroon to fund the development of its Minim Martap Bauxite Project in Cameroon, alongside additional funding from its major shareholder, Eagle Eye Asset Holdings [1][2][7]. Group 1: Credit Facility Details - The credit facility amounts to XAF 82,000,000,000 (approximately US$140 million) and is structured as a syndicated medium-term loan [11]. - The interest rate for the facility is fixed at 8.00% per annum plus VAT, with a repayment term of 8 years from the first drawdown [11]. - The drawdown is anticipated to occur in Q3 2025, with conditions including the opening of project accounts and guarantees from Canyon Resources Limited [3][11]. Group 2: Project Development - The funds from the credit facility will be utilized for acquiring locomotives, wagons, and developing rail and port infrastructure for the Minim Martap Bauxite Project [2]. - Since obtaining the Mining License in September 2024, Canyon has made significant progress, including securing key land for port and rail facilities, and is now focused on making a Final Investment Decision [5][6]. - The company aims to commence its first shipment of bauxite from Minim Martap in the first half of 2026 [5]. Group 3: Stakeholder Support - Eagle Eye Asset Holdings intends to exercise 350 million options for AU$24.5 million to further support the funding of Stage One operations at Minim Martap [2][7]. - AFG Bank Cameroon is recognized as a strong partner for Canyon, demonstrating expertise in structured financing and commitment to providing tailored financial solutions [4][7].
Perpetua Resources Submits Formal Application to Export-Import Bank of the United States to Finance the Stibnite Gold Project
Prnewswire· 2025-05-23 11:00
Core Viewpoint - Perpetua Resources Corp. has submitted a formal application to the Export-Import Bank of the United States (EXIM) for potential debt financing of up to $2 billion to construct the Stibnite Gold Project, which aims to establish a domestic source of antimony and produce gold [2][3][4]. Group 1: Project Financing and Application - The application amount has increased from $1.8 billion to $2 billion, reflecting a higher estimated number of job-years based on recent financial updates and engineering work [1][3]. - EXIM is expected to conduct standard due diligence on the application, assessing the project's eligibility under relevant initiatives [2][3]. - The financing, if approved, could cover a majority of the project's development costs, enhancing the U.S. competitive position against China in antimony production [5][6]. Group 2: Strategic Importance of the Project - The Stibnite Gold Project is positioned as a national strategic asset for domestic antimony production and is also recognized as a world-class gold asset [4][5]. - The project aims to restore a secure supply of antimony for the U.S., which is critical for national defense, especially after China blocked global antimony exports in 2024 [5][6]. - Perpetua Resources has received a Technology Investment Agreement of $59.2 million in Defense Production Act funding to advance the project [7]. Group 3: Regulatory and Permitting Progress - Perpetua has received its final federal permit, the Clean Water Act Section 404 permit, marking the end of an eight-year federal permitting process [6]. - The company is now focused on obtaining remaining state permits and securing financing to commence construction [6][7].
GENFIT Reports First Quarter 2025 Financial Information
Globenewswire· 2025-05-22 20:10
Core Viewpoint - GENFIT reported a significant increase in cash position and revenues for the first quarter of 2025, driven by a non-dilutive royalty financing agreement and royalties from Iqirvo® sales, indicating a strong financial outlook for the company. Cash Position - As of March 31, 2025, the company's cash and cash equivalents were €129.5 million, up from €74.0 million on March 31, 2024, and €81.8 million on December 31, 2024 [2][3] - The increase in cash is attributed to a €130.0 million first installment from a royalty financing agreement with HCRx, offset by the repurchase of OCEANEs totaling €61.7 million [3] Revenues - Revenues for the first three months of 2025 were €2.8 million, compared to €1.1 million for the same period in 2024, reflecting a substantial growth [4] - The revenue increase is primarily due to royalties from Iqirvo® (elafibranor) sales from Ipsen [4] Corporate Governance Update - Chief Medical Officer Carol Addy will retire effective June 30, 2025, with a replacement to be announced later [6] - CEO Pascal Prigent expressed gratitude for Addy's contributions to the company [6] Company Overview - GENFIT is focused on developing treatments for rare and life-threatening liver diseases, with a strong emphasis on Acute-on-Chronic Liver Failure (ACLF) [7] - The company has a diversified R&D portfolio, including multiple assets under development targeting various liver diseases and related conditions [8][9]